Morimatsu recently supplied bioreactors to NIBRT in Ireland, supporting advanced research in the field of biomedicine.

Ireland's strategic location, abundant talent pool, and robust research infrastructure make it an ideal environment for the growth of the biopharmaceutical industry. These advantages have attracted global companies, driving rapid industry expansion. Today, Ireland stands as a one of the world's leading centers for biopharmaceutical research and development, home to a plethora of renowned pharmaceutical and biotechnology companies.

About NIBRT

NIBRT (the National Institute for Bioprocessing Research and Training) is a key institution jointly established by Ireland's Foreign Direct Investment Agency and the Irish government. Its core mission is to provide training and research solutions for Ireland's biopharmaceutical companies, driving industry's development and innovation. By integrating talent development and scientific research innovation in the biopharmaceutical industry, NIBRT plays a pivotal role in strengthening Ireland's leadership in the global biopharmaceutical industry.

Morimatsu has gained extensive technical expertise in the field of bioreactors, supplying NIBRT with glass bioreactors and Wave Single-Use Bioreactor. These solutions support NIBRT's mission to equip trainees and researchers with access to the latest industry-leading technologies.

Morimatsu's state-of-the-art bioreactors can facilitate process development, research, seed training, as well as adherence to current Good Manufacturing Practices (cGMP). They will be incorporated into NIBRT's customized training programs that include short courses for both industry professionals and academics. Participants will gain hands-on experience with these technologies as part of courses focused on upstream processing operations, commissioning and qualification, and cell culture scale-up. This practical training will help enhance their professional skills in practical applications.

Bing minds together and share resources. Morimatsu stays tuned to the latest technological advancements. By collaborating with global life sciences institutions, Morimatsu fosters knowledge exchange, supports groundbreaking research, and accelerates advancements in biomedicine and bioprocessing. These efforts will drive progress and contribute to improving human health.

About Morimatsu LifeSciences

Morimatsu LifeSciences, one of the key business segments of Morimatsu International Holding Co., Ltd. (Morimatsu International, stock code: 2155.HK), mainly consists of Shanghai Morimatsu Pharmaceutical Equipment Engineering Co., Ltd., Morimatsu (Suzhou) Life Technology Co., Ltd., Shanghai Morimatsu Biotechnology Co., Ltd., Pharmadule Morimatsu AB (Sweden) and its subsidiaries, which serves the pharmaceuticals, bio-pharmaceutical, cosmetic medicine, FMCG (cosmetics, baby, women & home Care, health care, fabric & home care, food, beverage, nutraceuticals) and other industries, providing customers with "core equipment+value-added services+digital intelligent overall factory solutions and services" ("MVP Solutions&Services"), focusing on core equipment, stainless steel process systems, disposable process systems, consumables, laboratory solutions, digital and modular factory solutions and services. 

As a diversified multinational company, Morimatsu has opened subsidiaries or advanced manufacture plants in China, Japan, Sweden, United States, India, Italy, Singapore, and has delivered different forms of products and services to more than 40 countries and regions so far, by its global footprint of an efficient and professional team.   

Forward-Looking Statements

The information in this press release may include some forward-looking statements. Such statements are essentially susceptible to considerable risks and uncertainties. The use of "predicted", "believed", "forecast", "planned" and/or other similar words/phrases in all statements related to our company is to indicate that the statements are forward-looking ones. Our Company undertakes no obligation to constantly revise such predicted statements.

Forward-looking statements are based on our Company management's current perspectives, assumptions, expectations, estimations, predictions and understanding of future affairs at the time of the making of such statements. Such statements are not guarantees of future development and are susceptible to the impact of risks, uncertainties and other factors; some are beyond the control of our Company and unpredictable. Subject to the influence of future changes and development in our business, competition environment, political, economic, legal and social conditions, the actual outcomes may differ significantly from the information contained in the forward-looking statements.